New antibody takes aim at Hard-to-Treat blood cancers
Disease control
Recruiting now
This early-stage trial tests a new antibody drug called 4A10 in 24 people with relapsed or hard-to-treat acute lymphoblastic leukemia or lymphoblastic lymphoma. 4A10 targets a protein on cancer cells to block growth signals and help the immune system attack them. The main goal is…
Phase: PHASE1 • Sponsor: Allterum Therapeutics, Inc • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC